Cyted Health
Cyted Health is a leading gastrointestinal molecular diagnostics company focused on the early detection and prevention of esophageal adenocarcinoma through innovative, minimally invasive diagnostics. Founded by experts at the University of Cambridge, the company has developed the EndoSign® platform, an FDA-cleared device for minimally invasive esophageal cell collection, paired with advanced biomarker testing. Cyted Health's technology has been widely adopted by the UK's National Health Service, completing over 35,000 tests, and is expanding its presence in the U.S. to enhance patient care and broaden its advanced diagnostics portfolio.
Leadership & Board
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $44M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $44M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 02, 2025 | Series B | $44.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| BGF | Series B |
| EQT Life Sciences | Series B |
| Advent Life Sciences | Series B |
| British Business Bank | Series B |
| Morningside | Series B |
| HCA Healthcare | Series B |
Similar Companies
A snapshot of private companies similar to Cyted Health, helping you discover and navigate related company profiles.
Related News and Analysis
